Guanghao Wu | biomaterials | Research Excellence Award

Published on by VR Research Awards

Prof. Guanghao Wu | biomaterials | Research Excellence Award 

Beijing Institute of Technology | China

Dr. Guanghao Wu, Associate Professor at the Beijing Institute of Technology, is an emerging leader in biomimetic micro/nano delivery systems, advanced imaging materials, and cell-based therapeutics for cardiovascular and cerebrovascular diseases. His academic training spans a Ph.D. in Chemical Engineering and Technology from the Beijing Institute of Technology and earlier degrees in biochemistry, molecular biology, and biological sciences from Hebei Normal University, followed by postdoctoral research focused on functional nanomedicine. Dr. Wu’s contributions integrate cell membranes, extracellular vesicles, micro/nanomotors, NIR-II emissive materials, and hybrid cell platforms to achieve precise diagnosis and intervention for stroke, atherosclerosis, and intracerebral hemorrhage. His funded projects include major grants from the National Natural Science Foundation of China, the Beijing Natural Science Foundation, China Postdoctoral Science Foundation special and general programs, international academic exchange initiatives, and multiple national key laboratory open projects, reflecting strong recognition of his research leadership. He has authored 32 documents, accumulated Citations by 1,184 documents, with a total of 1,326 citations and an h-index of 16, demonstrating growing academic influence. His publications appear in top-tier journals such as Progress in Materials Science, ACS Nano, ACS Applied Materials & Interfaces, Soft Robotics, Angewandte Chemie International Edition, Biomaterials, Journal of Nanobiotechnology, Nano Research, and International Journal of Pharmaceutics, covering advancements in inflammation-responsive nanotherapies, hybrid stem cell–platelet systems, imaging-guided intervention platforms, soft actuators, and nanomedicine for fibrosis and vascular disease. His patented technologies further support his translational focus. Dr. Wu also serves on the Early-Career Editorial Boards of Acta Materia Medica, Biomedical Technology, Nano-Micro Letters, Interdisciplinary Medicine, and Biomedical Sciences, highlighting his standing in the scientific community. His innovations in biomimetic probes, NIR-II integrated hybrid cell therapy, and magnetic biomimetic cilia for real-time hemodynamic sensing contribute significantly to precision diagnostics and minimally invasive treatment strategies, positioning him as a competitive candidate for the Research Excellence Award.

Profile:  Scopus

Featured Publications

Wu, G., Yin, G., Zheng, Y. F., Li, M., & Luo, Y. M. (2025). Breaking through barrier: The emerging role of nucleic acids-based drug delivery in stroke. Progress in Materials Science, 151, 101436.

Song, J. C., Li, Y., Xu, B. Q., Wu, G.*, & Guo, Y. B. (2025). Centimeter-scale bulk liquid crystal elastomer artificial muscle with strong mechanical properties and designable complex shape-morphing. ACS Applied Materials & Interfaces, 17(21), 31476–31486.

Xu, B. Q., Xiao, X., Song, J. C., Zeng, X. B., Li, L., Duan, R., Jiang, M. D., Yin, Y., & Wu, G.* (2025). Multifunctional origami-inspired bimodal wireless pneumatic soft actuator. Soft Robotics.

Wu, G., & Xie, H., et al. (2023). Enhanced proliferation of visualizable mesenchymal stem cell−platelet hybrid cell for versatile intracerebral hemorrhage treatment. ACS Nano, 17(8), 7352–7365.

Wu, G., & Xie, H., et al. (2020). Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angewandte Chemie International Edition, 59(10), 4068–4074.

Wu, G., & Xie, H., et al. (2020). A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis. Biomaterials, 250, 119963.

Wu, G., Su, Q., Ge, H., et al. (2023). NAMPT encapsulated by extracellular vesicles from young adipose‑derived mesenchymal stem cells treated tendinopathy in a “one-stone-two-birds” manner. Journal of Nanobiotechnology, 21, 7.

Zheng, M., & Wu, G.* (2024). Traditional Chinese medicine inspired dual-drugs loaded inhalable nano-therapeutics alleviated idiopathic pulmonary fibrosis by targeting early inflammation and late fibrosis. Journal of Nanobiotechnology, 22, 14.